Novel Probiotic Strains with Antimicrobial and Barrier-Protective Properties

The primary value of this invention lies in its functional mechanism, which combines significant pathogen inhibition andproven epithelial barrier protection.

Technology

The global rise in antimicrobial resistance (AMR) among pathogens like Salmonella Typhimurium and ESBL- producing E. coli has led to increased mortality and significant economic losses. This crisis poses a severe threat to human, animal, and environmental health, necessitating a shift away from traditional antibiotics toward safer, scientifically validated alternatives. While probiotics are a promising solution, many existing products lack integrated genomic-phenotypic validation and fail to demonstrate clear mechanistic functions, such as pathogen exclusion or maintainance of intestinal barrier integrity. Consequently, there is an urgent need for novel, scientifically validated probiotic strains that can survive harsh gastrointestinal conditions and provide measurable health benefits. University of Delaware researchers have identified three taxonomically confirmed lactic acid bacterial strains, namely, Leuconostoc pseudomesenteroides MLS3, Lactococcus lactis MLS12, and Leuconostoc lactis MLS22. These strains, along with their cell-free supernatants (CFS. i.e. postbiotics), have been rigorously validated through whole-genome sequencing to confirm the absence of AMR genes and the presence of secondary metabolite pathways. The strains demonstrate exceptional gastrointestinal resilience, maintaining high viability (≥8 log CFU/mL) when exposed to acid, bile, and lysozyme. The technology utilizes a multi-level validation approach including microscopic imaging of pathogen damage and in vivo C. elegans survival assays to prove the strains’ ability to inhibit resistant pathogens and protect epithelial barriers against inflammation-induced damage. The technology also includes cell-free supernatants (CFSN), or postbiotics. The CFS postbiotics retain antimicrobial, efflux-inhibitory, and barrier-protective properties independent of live cells, offering enhanced formulation stability compared to live-cell-only products and enabling applications where live organism viability cannot be guaranteed. The primary value of this invention lies in its dual functional mechanism, which combines robust pathogen inhibition with proven epithelial barrier protection. This high level of validation meets increasing regulatory demands for functional evidence and mechanistic credibility. Additionally, the technology’s versatility allows it to be adapted for diverse markets.

Benefits

  • Rigorous Scientific Validation: Whole-genome sequencing to confirm species safety, the absence of AMR genes, and the presence of health-promoting metabolic pathways. Phenotypic testing independently confirms no AMR phenotypes, providing dual-layer safety assurance.
  • Dual-Modal-Action Protection: Provides a dual-modal functional mechanism that simultaneously inhibits dangerous pathogens and strengthens the intestinal barrier against inflammation.
  • Enhanced Stability and Shelf Life: CFS postbiotics retain full antimicrobial, efflux-inhibitory, and barrier-protective activity, ensuring the product remains effective in formulations where live probiotics often fail.
  • Market Versatility: A highly adaptable technology suitable for diverse applications, including fermented foods, dietary supplements, veterinary feed, and pharmaceutical therapeutics.

Applications

  • Functional Foods and Beverages
  • Dietary Supplements
  • Postbiotic-based therapeutics for gut health and infection prevention
  • Animal feed additives for poultry and livestock
  • Antibiotic adjuvant platforms for combating antimicrobial resistance
  • Iron absorption enhancement in inflamed population (postbiotic hepcidin modulation)